Skip to main content
Journal cover image

Monoclonal antibody therapy of human gliomas: current status and future approaches.

Publication ,  Journal Article
Wikstrand, CJ; Cokgor, I; Sampson, JH; Bigner, DD
Published in: Cancer Metastasis Rev
1999

The development of immunotherapeutic protocols for the treatment of human CNS neoplasia over the past two decades has been impressive. Several crucial aspects have been defined, characterized, and in many cases, optimized (Wikstrand CJ, Zalutsky MR, Bigner DD: In: Liau LM, Bigner DD (eds) Brain Tumor Immunotherapy. Humana Press (in press), 2000). Specific Mabs or constructs reacting with targetable antigens are currently available and in clinical trial. In addition, additional antigens currently under study (angiogenesis-related markers, developmentally associated antigens for medulloblastoma such as L1, and the identification of new targets by SAGE, just in its infancy, will provide a veritable library of available targets for therapy. The molecular engineering and affinity maturation techniques being applied to Mab fragment optimization have already been rapidly effective in generating a variety of Mab constructs of appropriate affinity for clinical trial; as new targets are defined, and experience is accrued with the various constructs currently and prospectively available, the optimal targeting of a multitude of antigens will be possible.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Cancer Metastasis Rev

DOI

ISSN

0167-7659

Publication Date

1999

Volume

18

Issue

4

Start / End Page

451 / 464

Location

Netherlands

Related Subject Headings

  • Protein Engineering
  • Oncology & Carcinogenesis
  • Immunotherapy
  • Humans
  • Glioma
  • ErbB Receptors
  • Brain Neoplasms
  • Antigens, Neoplasm
  • Antibodies, Monoclonal
  • Animals
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Wikstrand, C. J., Cokgor, I., Sampson, J. H., & Bigner, D. D. (1999). Monoclonal antibody therapy of human gliomas: current status and future approaches. Cancer Metastasis Rev, 18(4), 451–464. https://doi.org/10.1023/a:1006354102377
Wikstrand, C. J., I. Cokgor, J. H. Sampson, and D. D. Bigner. “Monoclonal antibody therapy of human gliomas: current status and future approaches.Cancer Metastasis Rev 18, no. 4 (1999): 451–64. https://doi.org/10.1023/a:1006354102377.
Wikstrand CJ, Cokgor I, Sampson JH, Bigner DD. Monoclonal antibody therapy of human gliomas: current status and future approaches. Cancer Metastasis Rev. 1999;18(4):451–64.
Wikstrand, C. J., et al. “Monoclonal antibody therapy of human gliomas: current status and future approaches.Cancer Metastasis Rev, vol. 18, no. 4, 1999, pp. 451–64. Pubmed, doi:10.1023/a:1006354102377.
Wikstrand CJ, Cokgor I, Sampson JH, Bigner DD. Monoclonal antibody therapy of human gliomas: current status and future approaches. Cancer Metastasis Rev. 1999;18(4):451–464.
Journal cover image

Published In

Cancer Metastasis Rev

DOI

ISSN

0167-7659

Publication Date

1999

Volume

18

Issue

4

Start / End Page

451 / 464

Location

Netherlands

Related Subject Headings

  • Protein Engineering
  • Oncology & Carcinogenesis
  • Immunotherapy
  • Humans
  • Glioma
  • ErbB Receptors
  • Brain Neoplasms
  • Antigens, Neoplasm
  • Antibodies, Monoclonal
  • Animals